WESTGOLD RESOURCES LTD ORDINARY SHARES (OTCMKTS:WTGRF) had an increase of 818.13% in short interest. WTGRF’s SI was 167,100 shares in May as released by FINRA. Its up 818.13% from 18,200 shares previously. With 1,500 avg volume, 111 days are for WESTGOLD RESOURCES LTD ORDINARY SHARES (OTCMKTS:WTGRF)’s short sellers to cover WTGRF’s short positions. The SI to WESTGOLD RESOURCES LTD ORDINARY SHARES’s float is 0.09%. It closed at $1.15 lastly. It is down 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.
Analysts expect Intec Pharma Ltd. (NASDAQ:NTEC) to report $-0.28 EPS on June, 8.After having $-0.39 EPS previously, Intec Pharma Ltd.’s analysts see -28.21% EPS growth. It closed at $4.85 lastly. It is up 25.00% since May 17, 2017 and is uptrending. It has outperformed by 13.45% the S&P500.
Among 4 analysts covering Intec Pharma (NASDAQ:NTEC), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intec Pharma had 9 analyst reports since September 11, 2015 according to SRatingsIntel. The stock of Intec Pharma Ltd. (NASDAQ:NTEC) earned “Buy” rating by Roth Capital on Thursday, August 3. TH Capital initiated Intec Pharma Ltd. (NASDAQ:NTEC) rating on Friday, September 11. TH Capital has “Buy” rating and $9.50 target. The company was initiated on Thursday, June 22 by Oppenheimer. Roth Capital initiated Intec Pharma Ltd. (NASDAQ:NTEC) rating on Friday, September 11. Roth Capital has “Buy” rating and $9.50 target. The firm has “Buy” rating by Oppenheimer given on Thursday, September 21. The firm earned “Buy” rating on Wednesday, September 16 by Maxim Group. The rating was maintained by Roth Capital with “Buy” on Monday, July 24. As per Thursday, August 10, the company rating was maintained by Roth Capital. The firm earned “Buy” rating on Thursday, November 16 by Oppenheimer.
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. The company has market cap of $164.22 million. The Company’s Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. It currently has negative earnings. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa , which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients.
Westgold Resources Limited engages in the exploration, development, mining, and treatment of gold assets in Western Australia. The company has market cap of $. The companyÂ’s principal assets include the Higginsville gold project, South Kalgoorlie gold project, Central Murchison gold project, Fortnum gold project, and Rover project. It has a 164.29 P/E ratio. It also explores for iron oxide, copper, lead, zinc, and silver deposits.